LLY241227C780000
- 2.00
- 0.000.00%
Eli Lilly and Co Newsroom
Sector Update: Health Care Stocks Weaker Late Afternoon
Sector Update: Health Care
Express News | Eli Lilly in Advanced Talks to Buy US Cancer Biotech for up to $2.5Bn- FT
Lilly Signs Licensing Deal With Mediar for IPF Drug
"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times
High-cost Weight Loss Drugs Are Sending Employers to Nutrition Counseling in a Boost for Startups
HIMS Downgraded, Agilon Upgraded at Citi in 2025 Health Tech Review
Express News | Andreessen Horowitz: Biotech Ecosystem Venture Fund Will Deploy up to $500 Mln to Invest in Companies at All Stages
Express News | Andreessen Horowitz Partners With Lilly to Launch First-of-Its-Kind Biotech Ecosystem Venture Fund
Express News | Mediar Therapeutics: Under Deal, Eligible to Get High-Single to Low-Double Digit Royalty Payments & Net Sales Milestones Based on Future Product Sales
Express News | Mediar Therapeutics: Under Agreement, Mediar to Receive Combined $99 Mln, Inclusive of Upfront Payment & Near-Term Milestones
Express News | Mediar Therapeutics: Global Licensing Agreement With Eli Lilly to Advance Mtx-463 Into a Phase 2 Clinical Trial for Idiopathic Pulmonary Fibrosis
On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To...
Eli Lilly and Company (NYSE:LLY) Delivered A Better ROE Than Its Industry
Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ
Morgan Stanley's outlook for the top ten investment trends in 2025: the revival of nuclear energy, the AI revolution in the financial Industry, quantum computing, oral weight loss medications...
Morgan Stanley pointed out that historically, popular themes with strong profit momentum tend to have a strong sustainability, such as AI, defense spending, and obesity drugs; negative prices and quantum computing are expected to emerge as new investment hotspots.
Two major pieces of news have come from Trump! Within a few hours after the inauguration ceremony, Trump will accomplish these significant tasks.
According to a report from Bloomberg on Thursday (January 9), the recently elected president of the USA, Donald Trump, plans to issue a series of executive orders within a few hours after his inauguration ceremony on January 20, addressing issues such as immigration, Energy, federal employees, and regulatory reforms. This is part of his comprehensive effort to swiftly implement his policy agenda after taking office.
Is Eli Lilly and Company (LLY) the Best Blue Chip Stock to Buy for 2025?
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference